Literature DB >> 9220050

Paclitaxel formulation as a cause of ethanol intoxication.

D B Wilson1, T M Beck, C A Gundlach.   

Abstract

OBJECTIVE: To report a case of ethyl alcohol intoxication associated with paclitaxel administration. CASE
SUMMARY: A patient who received a 3-hour paclitaxel infusion for metastatic breast carcinoma and developed symptoms of acute alcohol intoxication. A blood ethanol concentration drawn at the end of the paclitaxel infusion was 97.8 mg/dL (0.098%). DISCUSSION: The amount of alcohol contained in paclitaxel is discussed. A review of the literature revealed one patient series where the highest blood alcohol concentration was one-third that seen in our patient.
CONCLUSIONS: Clinicians should recognize the potential for alcohol intoxication with paclitaxel administration. This is especially pertinent when higher doses are given over a short period of time.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220050     DOI: 10.1177/106002809703100714

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  4 in total

Review 1.  Progress in the development of alternative pharmaceutical formulations of taxanes.

Authors:  B Nuijen; M Bouma; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Design and evaluation of an emulsion vehicle for paclitaxel. I. Physicochemical properties and plasma stability.

Authors:  Jihong Han; Stanley S Davis; Catherine Papandreou; Colin D Melia; Clive Washington
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

Review 3.  Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.

Authors:  Jörg T Hartmann; Hans-Peter Lipp
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.

Authors:  F Doz; J C Gentet; F Pein; D Frappaz; P Chastagner; S Moretti; G Vassal; J Arditti; O V Tellingen; A Iliadis; J Catalin
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.